Europe Wound Biologics Market - Focused Insights 2023-2028

Europe Wound Biologics Market - Focused Insights 2023-2028

REPORT OVERVIEW

This report offers market size & forecast data for the wound biologics market in Europe. The revenue generated from the sale of wound biologics products are included in the report. This report provides a comprehensive and current market scenario of the Europe wound biologics market, including Europe wound biologics market size, anticipated market forecast, relevant market segmentations, and industry trends.

The study considers a detailed scenario of the present wound biologics market and its market dynamics for 2023−2028 in Europe. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent players operating in the market.

MARKET DEFINITION

The products derived from living organisms or cells for treating wounds are called wound biologics. These are intended to facilitate the re-establishment of innate repair mechanisms.

KEY HIGHLIGHTS

• In Europe, the wound biologics market was valued at $420.00 million in 2022 and is expected to reach $710.02 million during the forecast period.
• By End-user, the specialty wound clinics accounted for the highest share of 54.33% in 2022 and are projected to grow at the highest CAGR of 9.51% during the forecast period. This is mainly due to the outsourcing by hospitals for wound treatment.
• By Product type, the biological skin substitutes segment accounted for the highest share of 59.44% in 2022 and is projected to grow at the highest CAGR of 8.81% during the forecast period. The increasing demand for biological skin substitutes is due to the rising number of diabetic wounds, increased preference for wound biologics, and the geriatric population.
• By Wound type, the chronic wounds segment accounted for the highest share of 54.55% in 2022 and is projected to grow at the highest CAGR of 9.64% during the forecast period. This is due to many factors, such as increasing cases of diabetes, obesity, and advanced age, that contribute to the rise in the number of chronic wound cases.
• The demand for wound biologics market is rising due to multiple factors, including an increasing geriatric population, growing consumer awareness regarding usage, high prevalence of chronic and acute wounds, and increasing adoption of wound biologics.
• Other factors such as technological & material advancements, introduction of new products, well-developed healthcare infrastructure, extensive research & development activities, presence of leading key vendors, and government support also contribute to the growth of the overall wound biologics market.

VENDORS LIST

• Avita Medical
• Organogenesis
• Smith+Nephew
• Vericel Corporation
• Orthofix
• MediWound
• Aurealis Therapeutics
• Kericis
• MiMedx
• Fidia
• Convatec
• AlloSource
• Cytori
• Ethicon
• Integra LifeSciences
• Medline Industries
• Marine Polymer Technologies
• Molnlycke
• Stryker
• BD
• Zimmer Biomet
• RedDress

REPORT HIGHLIGHTS

PRODUCT SEGMENTATION & FORECAST

• By Product
• Biological Skin Substitutes
• Growth Factors
• By Wound Type
• Chronic Wounds
• Acute Wounds
• End-user
• Specialty Wound Care Clinics
• Hospitals
• Long-Term Care Centers

MARKET STRUCTURE

• Market Dynamics
• Competitive Landscape of Wound Biologics Market
• Key Vendors
• Other Prominent Vendors

APPENDIX

• Research Methodology
• Abbreviations
• About Arizton